title: Therapeutic approaches in hereditary angioedema.
abstract: Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not available worldwide, can improve disease outcome due to their different mechanisms of action.
authors.affiliation: Gr T Popa University of Medicine and Pharmacy Iaşi, Department of Medicine II-Pulmonary Disease, Pulmonary Disease University Hospital, Iaşi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
authors.forename: Sabina Antonela
authors.initials: SA
authors.lastname: Antoniu
mesh_terms: D054179:Angioedemas, Hereditary / Q000097:blood / Q000188:drug therapy*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D065168:Bradykinin Receptor Antagonists; D002986:Clinical Trials as Topic; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D065168:Bradykinin Receptor Antagonists; D050718:Complement C1 Inhibitor Protein; D010455:Peptides; D011994:Recombinant Proteins; C511194:ecallantide; C065679:icatibant; D007610:Kallikreins; D001920:Bradykinin